Search Results - "Maloney, D.G"

Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil by Li, H., Mager, D.E., Sandmaier, B.M., Maloney, D.G., Bemer, M.J., McCune, J.S.

“…We sought to create a population pharmacokinetic model for total mycophenolic acid (MPA), to study the effects of different covariates on MPA pharmacokinetics,…”
Get full text

OP61 Stem cell allotransplantation for NHL by Maloney, D.G

Get full text

PCN90 ASSESSMENT OF UTILITIES FOR ADVERSE EVENTS (AES) ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA (LBCL) by Howell, T., Matza, L., Jun, M.P., Garcia, J., Powers, A., Maloney, D.G.

Get full text

Chimeric antigen receptor-modified T cells derived from defined [CD8.sup.+] and [CD4.sup.+] subsets confer superior antitumor reactivity in vivo by Sommermeyer, D, Hudecek, M, Kosasih, P.L, Gogishvili, T, Maloney, D.G, Turtle, C.J, Riddell, S.R

“…Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor or chimeric antigen receptor (CAR) is a rapidly growing field of…”
Get full text

Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma by Holmberg, L.A, Maloney, D.G, Bensinger, W.I

Get full text

Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome by Lechowicz, M J, Lazarus, H M, Carreras, J, Laport, G G, Cutler, C S, Wiernik, P H, Hale, G A, Maharaj, D, Gale, R P, Rowlings, P A, Freytes, C O, Miller, A M, Vose, J M, Maziarz, R T, Montoto, S, Maloney, D G, Hari, P N

“…We describe outcomes after allogeneic hematopoietic cell transplantation (HCT) for mycosis fungoides and Sezary syndrome (MF/SS). Outcomes of 129 subjects with…”
Get full text

An algorithm for suboptimally placed supraglottic airway devices: the choice of videolaryngoscope by Tobin, S.P., Maloney, D.G., Walker, J.D.

Get full text

A Randomized Phase III Trial Investigating 2 Gy TBI Vs. Flu/2 Gy TBI Conditioning for HLA-Matched Related Donor Hematopoietic Cell Transplantation (HCT): Tempo of CD3 and NK Cell Engraftment Determines Relapse and Progression Free Survival in Patients with Hematologic by Kornblit, B, Storer, B, Storb, R.F, Hari, P, Vucinic, V, Maziarz, R.T, Chauncey, T, Pulsipher, M.A, Bruno, B, Petersen, F.B, Bethge, W.A, Hubel, K, Storek, J, Maloney, D.G, Sandmaier, B.M

Get full text

Association Between Calcineurin Inhibitor Blood Concentrations and Outcomes After Allogeneic Hematopoietic Cell Transplantation by Ram, R, Storer, B.E, Sandmaier, B.M, Mielcarek, M, Maloney, D.G, Martin, P.J, Flowers, M.E.D, Chua, B.K, Rotta, M, Storb, R

Get full text

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma by Graf, S.A., Stevenson, P.A., Holmberg, L.A., Till, B.G., Press, O.W., Chauncey, T.R., Smith, S.D., Philip, M., Orozco, J.J., Shustov, A.R., Green, D.J., Libby, E.N., Bensinger, W.I., Pagel, J.M., Maloney, D.G., Zhou, Y., Cassaday, R.D., Gopal, A.K.

“…High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs…”
Get full text

Tandem Autologous and Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-matched Related Or Unrelated Donors for Advanced Lymphoma Or Chronic Lymphocytic Leukemia (CLL) by Sorror, M.L, Storer, B, Sandmaier, B.M, Chauncey, T, Storb, R.F, Maloney, D.G

Get full text

A randomized study of melphalan 200 mg/[m.sup.2] vs 280 mg/[m.sup.2] as a preparative regimen for patients with multiple myeloma undergoing auto-SCT by Bensinger, W.I, Becker, P.S, Gooley, T.A, Chauncey, T.R, Maloney, D.G, Gopal, A.K, Green, D.J, Press, O.W, Lill, M, Ifthikharuddin, J.J, Vescio, R, Holmberg, L.A, Phillips, G.L

“…We aimed to examine whether doses of melphalan higher than 200 mg/[m.sup.2] Improve response rates when used as conditioning before autologous transplant…”
Get full text

275: Impacts of comorbidities on outcomes of patients (pts) younger than 60 years old, diagnosed with indolent malignancies and treated with allogeneic hematopoietic cell transplantation (HCT) by Sorror, M.L, Storb, R, Storer, B, Maloney, D.G, Sandmaier, B.M

Get full text

Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor by Bachanova, V, Burns, L J, Wang, T, Carreras, J, Gale, R P, Wiernik, P H, Ballen, K K, Wirk, B, Munker, R, Rizzieri, D A, Chen, Y-B, Gibson, J, Akpek, G, Costa, L J, Kamble, R T, Aljurf, M D, Hsu, J W, Cairo, M S, Schouten, H C, Bacher, U, Savani, B N, Wingard, J R, Lazarus, H M, Laport, G G, Montoto, S, Maloney, D G, Smith, S M, Brunstein, C, Saber, W

“…Alternative donor transplantation is increasingly used for high-risk lymphoma patients. We analyzed 1593 transplant recipients (2000–2010) and compared…”
Get full text

CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY BASELINE TUMOR BURDEN IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL by Maziarz, R.T., Schuster, S.J., Ericson, S.G., Rusch, E.S., Signorovitch, J., Li, J., Romanov, V.V., Maloney, D.G., Locke, F.L.

Get full text

A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA by Lynch, R.C., Smith, S.D., Shadman, M., Ujjani, C.S., Kurtz, D.M., Coye, H., Till, B.G., Warren, E.H., Shustov, A.R., Maloney, D.G., Tseng, Y.D., Gopal, A.K.

Get full text

SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULTS AFTER CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR‐MODIFIED T‐CELL (CAR‐T) THERAPY by Shadman, M., Gauthier, J., Hay, K.A., Voutsinas, J.M., Milano, F., Li, A., Hirayama, A.V., Sorror, M.L., Cassaday, R.D., Till, B.G., Gopal, A.K., Sandmaier, B.M., Maloney, D.G., Turtle, C.J.

Get full text

Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma by Maloney, D G

“…Allogeneic hematopoietic SCT following myeloablative conditioning is associated with a high nonrelapse mortality and usually reserved for young, medically fit…”
Get full text

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY by Hirayama, A.V., Gauthier, J., Hay, K.A., Voutsinas, J.M., Wu, Q., Sheih, A., Purushe, J., Pender, B.S., Hawkins, R.M., Vakil, A., Phi, T., Steinmetz, R.N., Riddell, S.R., Maloney, D.G., Turtle, C.J.

Get full text

Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure by Gauthier, J., Hirayama, A.V., Hay, K.A., Lymp, J., Li, D., Sheih, A., Purushe, J., Pender, B.S., Hawkins, R.M., Vakil, A., Phi, T., Steinmetz, R.N., Riddell, S.R., Maloney, D.G., Turtle, C.J.

Get full text